Profile

We contribute to improve cancer diagnostics

The number of people suffering from cancer is constantly growing. A key factor in ensuring patients the best treatment is to make an accurate and full diagnosis and choose the right form of treatment at an early stage.

"At Dako we build our business to constantly improve cancer diagnostics. The pathology lab is where all cancer related diagnoses are being prepared and where we have our main focus. By focusing on the entire workflow of the pathology labs worldwide we believe that we can contribute in improving quality, safety and cost efficiency for the benefit of the doctors, the lab and especially the patients waiting for results,” says Patrik Dahlén, CEO at Dako.

The strategic focus of Dako is centered on workflow in the pathology laboratory with the aim of:

1.Reducing time from biopsy to diagnosis

2.Improving quality and reliability of the diagnosis

3.Reducing laboratory costs.

Our goal is to help our customers help their patients the most human way possible. We work closely with doctors and experts in the field of cancer diagnostics to ensure we stay at the forefront of their needs and the market development. Partnering is a way for us to get access to relevant technologies outside our own core competencies.

We aim to be an attractive partner and employer and have a highly trained and skilled international staff to develop, manufacture and market our products all over the world. Our organization is spread world wide. We stay in close relations and support openness and dialogue as an important element in the way we work.

Dako is a global business with headquarters in Denmark. It was founded by the Danish medical doctor Niels Harboe in 1966 and has more than 40 years' experience in the development and production of reagents and antibodies.